Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background Atezolizumab (a monoclonal antibody against PD-L1), which restores
anticancer immunity, improved overall survival in patients with previously treated non-small …

PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …

Objectives To identify the cooperation of authors, countries, and institutions and explore the
hot topics and future prospects regarding programmed cell death protein 1 (PD-1) and …

Immunotherapy, which stimulates the body's immune system, has received a considerable
amount of press in recent years because of its powerful benefits. Cancer immunotherapy …

Introduction Dysfunction of the immune system is a hallmark of cancer. Through increased
understanding of the complex interactions between immunity and cancer, immunotherapy …

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-
PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 …